Screening for hereditary hemochromatosis: A systematic review for the U.S. preventive services task force

Annals of Internal Medicine

Volumn 145, Issue 3, 2006, Pages 209-223

  Whitlock, Evelyn P ^a   Garlitz, Betsy A ^a,b   Harris, Emily L ^a   Beil, Tracy L ^a   Smith, Paula R ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; GENETIC DISORDER; GENOTYPE; HEALTH SERVICE; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; MORBIDITY; PHENOTYPE; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW; COST OF ILLNESS; ECONOMICS; ETHICS; EVIDENCE BASED MEDICINE; GENETIC SCREENING; GENETICS; HOMOZYGOTE; PENETRANCE;

COST OF ILLNESS; EVIDENCE-BASED MEDICINE; GENETIC SCREENING; HEMOCHROMATOSIS; HOMOZYGOTE; HUMANS; PENETRANCE; PHLEBOTOMY; RISK FACTORS;

EID: 33746830877     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-3-200608010-00009     Document Type: Review

References (81)

1. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins; 1996.
2. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions. Baltimore: Williams & Wilkins; 1989.
3. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med. 2004;350:2383-97.
4. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol. 2000;33:485-504.
5. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med. 1993;328:1616-20.
6. Powell LW, Isselbacher KJ. Hemochromatosis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Long DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2001:2257-61.
7. DuBois S, Kowdley KV. Review article: targeted screening for hereditary haemochromatosis in high-risk groups. Aliment Pharmacol Ther. 2004;20:1-14.
8. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
9. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001;154:193-206.
10. Edwards CQ, Ajioka RS, Kushner JP. Hemochromatosis: a genetic definition. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:8-11.
11. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769-78.
12. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med. 1998;129:946-53.
13. Adams PC. Hemochromatosis. Clin Liver Dis. 2004;8:735-53, vii.
14. Piperno A. Expression of iron overload in hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:177-83.
15. Baynes RD. Interactions of alcohol, iron and hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:468-74.
16. Njajou OT, Alizadeh BZ, van Duijn CM. Is genetic screening for hemochromatosis worthwhile? Eur J Epidemiol. 2004;19:101-8.
17. Brissot P. Clinical spectrum of hepatic disease in hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:250-7.
18. Sham RL, Raubertas RF, Braggins C, Cappuccio J, Gallagher M, Phatak PD. Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles. Blood. 2000;96:3707-11.
19. Hemochromatosis for Health Care Professionals. Diagnostic testing protocol. Centers for Disease Control and Prevention. Accessed at www.cdc.gov/hemochromatosis/training/diagnostic_testing/testing_protocol.htm on 27 September 2005.
20. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol. 2001;96:567-9.
21. Baldus WP, Batts KP, Brandhagen DJ. Liver biopsy in hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge Univ Pr; 2000:187-99.
22. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-62.
23. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci. 1988;526:245-57.
24. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol. 2002;16:297-302.
25. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991;101:368-72.
26. Eijkelkamp EJ, Yapp TR, Powell LW. HFE-associated hereditary hemochromatosis. Can J Gastroenterol. 2000;14:121-5.
27. Cadet E, Capron D, Gallet M, Omanga-Leke ML, Boutignon H, Julier C, et al. Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases? J Med Genet. 2005;42:390-5.
28. Brown AS, Gwinn M, Cogswell ME, Khoury MJ. Hemochromatosis- associated morbidity in the United States: an analysis of the National Hospital Discharge Survey, 1979-1997. Genet Med. 2001;3:109-11.
29. Ajioka RS, Kushner JP. Hereditary hemochromatosis. Semin Hematol. 2002;39:235-41.
30. McDonnell SM, Witte DL, Cogswell ME, McIntyre R. Strategies to increase detection of hemochromatosis. Ann Intern Med. 1998;129:987-92.
31. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36:1108-15.
32. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211-8.
33. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen. 1996;3:178-84.
34. Cogswell ME, McDonnell SM, Khoury MJ, Franks AL, Burke W, Brittenham G. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med. 1998;129:971-9.
35. McDonnell SM, Parrish RG. Hereditary hemochromatosis and its elusive natural history. Arch Intern Med. 2003;163:2421-3; author reply 2427.
36. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis. A public health perspective. Am J Prev Med. 1999;16:134-40.
37. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins C, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med. 1998;129:954-61.
38. Niederau C, Niederau CM, Lange S, Littauer A, Abdel-Jalil N, Maurer M, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 1998;128:337-45.
39. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta. 1996;245:139-200.
40. Brittenham GM, Franks AL, Rickles FR. Research priorities in hereditary hemochromatosis. Ann Intern Med. 1998;129:993-6.
41. Waalen J, Nordestgaard BG, Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol. 2005;18:203-20.
42. Feldman M, Tschumy WO, Friedman LS, Sleisenger MH. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 7th ed. New York: Elsevier; 2002.
43. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology. 2001;33:1321-8.
44. McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci. 2003;325:53-62.
45. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med. 1998;129:925-31.
46. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004;79:309-13.
47. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914-9.
48. Beutler E, Felitti V, Ho NJ, Gelbart T. Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol. 2002;107:145-9.
49. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329-37.
50. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Penetrance of hemochromatosis. Blood Cells Mol Dis. 2002;29:418-32.
51. Deugnier Y, Jouanolle AM, Chaperon J, Moirand R, Pithois C, Meyer JF, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol. 2002;118:1170-8.
52. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-24.
53. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998;43:830-6.
54. Distante S, Berg JP, Lande K, Haug E, Bell H. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol. 1999;34:529-34.
55. McDonnell SM, Hover A, Gloe D, Ou CY, Cogswell ME, Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med. 1999;107:30-7.
56. Delatycki MB, Allen KJ, Nisselle AE, Collins V, Metcalfe S, du Sart D, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet. 2005;366:314-6.
57. Barton JC, Rothenberg BE, Bertoli LF, Acton RT. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med. 1999;1:89-93.
58. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294-301.
59. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med. 1976;45:611-23.
60. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-19.
61. Cadet E, Capron D, Perez AS, Crepin SN, Arlot S, Ducroix JP, et al. A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis. J Intern Med. 2003;253:217-24.
62. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med. 2002;113:472-9.
63. Poullis A, Moodie SJ, Ang L, Finlayson CJ, Levin GE, Maxwell JD. Routine transferrin saturation measurement in liver clinic patients increases detection of hereditary haemochromatosis. Ann Clin Biochem. 2003;40:521-7.
64. Moodie SJ, Ang L, Stenner JM, Finlayson C, Khotari A, Levin GE, et al. Testing for haemochromatosis in a liver clinic population: relationship between ethnic origin, HFE gene mutations, liver histology and serum iron markers. Eur J Gastroenterol Hepatol. 2002;14:223-9.
65. Willis G, Scott DG, Jennings BA, Smith K, Bukhari M, Wimperis JZ. HFE mutations in an inflammatory arthritis population. Rheumatology (Oxford). 2002;41:176-9.
66. Swinkels DW, Aalbers N, Elving LD, Bleijenberg G, Swanink CM, van der Meer JW. Primary haemochromatosis: a missed cause of chronic fatigue syndrome? Neth J Med. 2002;60:429-33.
67. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35.
68. The Cochrane Non-Randomised Studies Methods Group. Accessed at www.cochrane.dk/nrsmg on 18 April 2005.
69. Phatak PD, Ryan DH, Cappuccio J, Oakes D, Braggins C, Provenzano K, et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis. 2002;29:41-7.
70. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology. 1998;114:319-23.
71. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. 2000;31:1160-4.
72. Sanchez M, Villa M, Ingelmo M, Sanz C, Bruguera M, Ascaso C, et al. Population screening for hemochromatosis: a study in 5370 Spanish blood donors. J Hepatol. 2003;38:745-50.
73. Chambers V, Sutherland L, Palmer K, Dalton A, Rigby AS, Sokol R, et al. Haemochromatosis-associated HFE genotypes in English blood donors: age-related frequency and biochemical expression. J Hepatol. 2003;39:925-31.
74. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis. Rockville, MD: Agency for Healthcare Research and Quality; 2006.
75. Williams R, Smith PM, Spicer EJ, Barry M, Sherlock S. Venesection therapy in idiopathic haemochromatosis. An analysis of 40 treated and 18 untreated patients. Q J Med. 1969;38:1-16.
76. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med. 1999;106:619-24.
77. Harrison H, Adams PC. Hemochromatosis. Common genes, uncommon illness? Can Fam Physician. 2002;48:1326-33.
78. Imperatore G, Pinsky LE, Motulsky A, Reyes M, Bradley LA, Burke W. Hereditary hemochromatosis: perspectives of public health, medical genetics, and primary care. Genet Med. 2003;5:1-8.
79. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med. 2005;143:522-36.
80. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK, et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;143:517-21.
81. Wetterhall SF, Cogswell ME, Kowdley KV. Public health surveillance for hereditary hemochromatosis. Ann Intern Med. 1998;129:980-6.